PRINCETON, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. plans to host a conference call and live audio webcast today at 10:00 a.m. Eastern time to discuss its collaboration for MDX-010 with Bristol- Myers Squibb Company. To access the call live, please dial 800-706-7741 within the U.S. or 617-614-3471 outside of the U.S. and enter passcode 76059039. The call will also be broadcast live via the Internet at http://www.medarex.com/Investor/Events.htm .
The webcast will be available on the Events page in the Investor Relations section of Medarex's website at http://www.medarex.com/ and will be archived for a limited time following the webcast. To access the archive, please dial 888-286-8010 within the U.S. or 617-801-6888 outside the U.S. and enter passcode 76623949.
Medarex is a biopharmaceutical company focused on the discovery and development of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb(TM) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Twenty of these therapeutic products derived from Medarex technology are currently in human clinical testing, with the most advanced candidate currently in a Phase III clinical trial. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com/ .
Medarex(R) and the Medarex logo are registered trademarks of Medarex, Inc. UltiMAb(TM) is a trademark of Medarex, Inc. All rights are reserved.
CONTACT: Laura S. Choi, Investor Relations for Medarex, +1-609-430-2880,ext. 2216; or media contact, Jean Mantuano, Corporate Communications forMedarex, +1-609-430-2880, ext. 2221